UPDATE: SVB Leerink Assumes Halozyme Therapeutics (HALO) at Outperform, 'Durability Underappreciated for This Partner of Choice'
Tweet Send to a Friend
(Updated - May 23, 2022 3:41 AM EDT)
SVB Leerink analyst David Risinger assumes coverage on Halozyme Therapeutics (NASDAQ ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
SVB Leerink analyst David Risinger assumes coverage on Halozyme Therapeutics (NASDAQ ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
